Interleukin‐2 Can Cure Kidney Cancer
نویسندگان
چکیده
منابع مشابه
Can Financial Engineering Cure Cancer?
The biotechnology and pharmaceutical industries are currently confronted with a conundrum: despite remarkable scientific breakthroughs over the past decade in our understanding of the molecular biology of disease, the financial returns to biopharma investments have been mediocre at best, and investors are withdrawing capital from this sector. Accordingly, there is a growing concern within and o...
متن کاملCan a macrobiotic diet cure cancer?
Myth: The macrobiotic diet, a common dietary alternative, can cure cancer. Answer: The various cultures present in the United States are filled with contradictions when it comes to nutrition. Americans are bombarded with fast food franchises and restaurants serving larger and larger portions of mass produced food. However, at the same time, media outlets and infomercials report on the obesity c...
متن کاملCancer: A Computational Disease that AI Can Cure
14 AI MAGAZINE Despite enormous strides in scientific understanding and medical treatment, cancer still kills millions of people each year. This article will explore why cancer has proven to be such a formidable adversary, and how AI and machine learning (ML) can save lives by helping individual patients beat the odds. Modern molecular biology supports the hypothesis that cancer is actually hun...
متن کاملCan We Cure Breast Cancer with Adjuvant Trastuzumab?
The news of the results from 3 recent trials of adjuvant trastuzumab treatment in early breast cancer, showing a large reduction in cancer recurrence in women with HER2-positive (HER2+) disease, is a major success for the concept of targeted therapy using biological agents. Because 20% to 30% of all newly diagnosed women have HER2+ breast cancer, making trastuzumab available to all those who st...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Oncologist
سال: 2018
ISSN: 1083-7159,1549-490X
DOI: 10.1634/theoncologist.2018-0038